Myriad Genetics (MYGN) may have lost its gene patents -- and potentially cost the pharma and biotech industries theirs -- based on a subtle, but ultimately colossal, misunderstanding of a 62-year-old court case called Funk Brothers. A New …
Analysts at William Blair believe a new deal with insurer UnitedHealthcare is in the cards, potentially providing coverage for Myriad’s GeneSight test. They believe the stock will outperform the broad stock market over the next 12 months.
NEW YORK, June 15, 2017 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ('Immune') announced today that it has signed an agreement with Meda, a Mylan NV company ('Mylan') to repurchase assets relating to Ceplene, …
It's hard being a trader shorting stocks. Short sellers, or investors betting that the price of a stock will go down, have to overcome unexpected fees, as well as simple math: you can only ever make 100% on a short position, but your losses …
Seattle Genetics (SGEN) was a big mover last session, as the company saw its shares rise nearly 8% on the day amid huge volumes.